首页|PROTAC分子的药代动力学特征及其在疾病治疗中的研究进展

PROTAC分子的药代动力学特征及其在疾病治疗中的研究进展

扫码查看
蛋白靶向裂解嵌合体(proteolysis-targeting chimera,PROTAC)作为一种新兴的治疗方式,经过二十年的研究和发展,目前俨然成为新药研发领域最火热的技术之一。PROTAC分子利用细胞中天然存在的泛素-蛋白酶体系诱导靶向蛋白降解,尤其是一些传统小分子难以靶向的目标蛋白,并且其有望解决使用小分子药物常出现的耐药性问题。然而,PROTAC分子由于分子量较大、溶解度及膜渗透性差,口服吸收低,使其成药性研究面临诸多挑战。目前,应以药代动力学特征为着力点,不断优化设计,以期加快PROTAC药物从实验室到临床应用的转化步伐。本综述介绍了 PROTAC分子的基本结构及作用机制,分析了其药代动力学特性及如何设计高效稳定的PROTAC分子,并总结了其目前在各类疾病治疗中的研究进展,评估了 PROTAC药物的发展前景及面临的局限性,为PROTAC药物的进一步研究应用提供参考。
Pharmacokinetics of PROTACs and their research progress in disease treatment
Proteolysis-targeting chimera(PROTAC),as an emerging treatment method,has become one of the hottest technologies in the field of new drug research with a near-20-year development.PROTAC utilizes the natural ubiquitin-protease system in cells to induce targeted protein degradation,especially for protein of interest that are difficult to target by traditional small molecules.Moreover,PROTAC is expected to solve the problem of drug resistance that often occurs with small molecule drugs.However,the excessive relative molecular weight,poor solubility and membrane permeability,and low oral absorption of PROTAC make it challenging to druggability study.Currently,take pharmacokinetic characteristics as the entry point to continuously optimize and improve,so as to accelerate the transformation of PROTAC from laboratory to clinical application.Based on the basic structure and mechanism of PROTACs,this review introduces its pharmacokinetic properties,analyzes how to design efficient and stable PROTAC molecules,summarizes its current research progress in various diseases treatments,evaluates the development prospects and limitations of PROTAC,in order to provide more references for further research and application of PROTAC.

proteolysis-targeting chimerapharmacokineticsdisease targeted therapy

吴瑾瑾、扈金萍

展开 >

中国医学科学院、北京协和医学院药物研究所,创新药物非临床药物代谢及PK/PD研究北京市重点实验室,北京 100050

蛋白靶向裂解嵌合体 药代动力学 疾病靶向治疗

2024

药学学报
中国药学会 中国医学科学院药物研究所

药学学报

CSTPCD北大核心
影响因子:1.274
ISSN:0513-4870
年,卷(期):2024.59(9)